JAK1 and precursor B-cell acute lymphoblastic leukemia: RAS pathway-activating mutations are found in 38% of relapsed pediatric B-ALL patients and additional mutations that activate the RAS signaling cascade (NF1, BRAF, IKZF2, IKZF3, JAK1) have also been found with varying frequencies in relapsed ALL [112].